Regulus added two new clinical drug candidates to treat liver and kidney diseases.
- PR Newswire•3 days ago
LA JOLLA, Calif., Dec. 6, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced two new drug development candidates at its R&D day, held in New York. "We are delighted to announce the addition of two new drug candidates to our growing portfolio of potential microRNA therapeutics.
- PR Newswire•17 days ago
LA JOLLA, Calif., Nov. 22, 2016 /PRNewswire/ -- Regulus Therapeutics Inc. (RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will host a R&D day on Tuesday, December 6, 2016 from 8:30 a.m. to 11:30 a.m. EST in New York City where it plans to announce new development candidates. Interested parties may access a live audio webcast and slides of the presentations on the investor section of Regulus' website at www.regulusrx.com beginning at 8:30 a.m. EST.
RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance
Regulus Therapeutics Inc. (RGLS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.40 x 1000|
|Ask||2.60 x 100|
|Day's Range||2.35 - 2.65|
|52 Week Range||2.13 - 10.18|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.91|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|